We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Ultra-Portable POC Molecular Diagnostics System to Instantly Detect Infectious Diseases

By HospiMedica International staff writers
Posted on 02 Feb 2024

Infectious diseases pose a significant threat to human health and have a substantial economic impact globally. More...

Timely and accurate identification of pathogens is key for prompt treatment, improved patient outcomes, and halting the spread of diseases. Traditional pathogen detection methods are usually conducted in well-equipped clinical labs, relying on advanced equipment and specialized staff. Furthermore, pre-analytical steps such as lengthy transportation can skew results and extend turnaround times (TAT), hindering effective control of infectious diseases, especially in areas with limited resources. Now, a rapid RT-PCR platform being developed to provide highly accurate, rapid, and affordable diagnoses of infectious diseases at point-of-care and near-patient settings could enable immediate treatment initiation and curtail potential disease transmission.

Novel Microdevices (Baltimore, MD, US) is advancing its affordable, portable, rapid, multiplex, and user-friendly PCR testing solution for infectious diseases. This innovative technology simplifies complex scientific processes, typically carried out in high-complexity labs, into a compact device. Point-of-care diagnostics offered by the Novel Dx device allow for immediate results, enabling prompt action instead of the extended waiting times associated with traditional laboratory tests. The Novel Dx device employs Nucleic Acid Amplification Techniques (NAAT), which is the same method used in clinical reference laboratories, to detect the genetic material of pathogens.

The Novel Dx molecular testing platform utilizes polymerase chain reaction (PCR) technology in a disposable cartridge. The patient's sample is added to this cartridge, which is then inserted into the Novel Dx system. The system analyzes genetic sequences to identify diseases and detect genetic mutations that may make bacteria resistant to antibiotics. Novel Dx is capable of providing lab-quality results in less than 15 minutes, allowing patients to be tested, diagnosed, and treated all within a single visit, thus eliminating the wait for results from more complex labs. Designed for portability and weighing just four pounds, the Novel Dx diagnostic tool is battery-operated, making it especially suitable for use in low-resource settings and low-and middle-income countries (LMICs).


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.